The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow
The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow for percutaneoustransluminal angioplasty (PTA) as well as the infusion of site-specificcontrast media for peripheral vascular anatomy (SCAN 2/15/95).The agency's most recent action allows Periflow to be marketedfor both PTA and the site-specific delivery of therapeutic pharmaceuticalsinto the peripheral vasculature. CVD, of Irvine, CA, plans tobegin U.S. shipments of Periflow by the end of this year.
In other news, Endosonics said CVD has received approval fromthe Japanese Ministry of Health to market its Controlled AngioplastyTechnology catheters in Japan.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.